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Acute exposure to high-altitude hypoxia induces impor-tant changes in cardiovascular regulation,1–4 including 
an increase in blood pressure (BP) and heart rate (HR).2,5–8 
Millions of subjects travel for relatively short periods of time 
to high altitude either for work or for leisure including many 
affected by hypertension9 in whom the pressor effect of high 
altitude may be relevant. Limited information is available, 
however, on the acute BP effects of high altitude in hyper-
tensive subjects,10 and on the effectiveness and tolerability of 
antihypertensive drugs under these circumstances. As a result, 
the few recommendations published on the management of 
hypertensive subjects planning to spend time at high altitude 
for either leisure or work are largely based on experts’ opinion 
rather than on evidence.2,11–14
Both angiotensin receptor blockers (ARBs) and dihydro-
pyridine calcium antagonists are widely used for the mono-
therapy of hypertension, and their combination has been 
included among the preferred therapeutic choices by recent 
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guidelines.15,16 Furthermore, the calcium antagonist nifedipine 
lowers pulmonary pressure typically elevated at high altitude 
and is used in prevention and treatment of high-altitude pul-
monary edema.4
Aims of the present study were to extend the information on 
the acute effects of high altitude on conventional and 24-hour 
BP obtained in previous studies in normotensive volunteers8,17 
to hypertensive subjects residing at sea level, and to determine 
whether the efficacy of antihypertensive treatment with the 
combination of an ARB (telmisartan) and a slow release cal-
cium antagonist (nifedipine gastrointestinal therapeutic sys-
tem [GITS]) is maintained at high altitude.
The study was conducted in the frame of the High Altitude 
Cardiovascular Research (HIGHCARE)–Andes Lowlanders 
Study.
Methods
This was a single-center, parallel-group, randomized, double-blind, 
controlled trial comparing the 24-hour BP effects of telmisartan 
80 mg combined with nifedipine gastrointestinal therapeutic system 
30 mg against placebo at sea level and at an altitude of 3260 m.
Participants
Subjects with known or suspected arterial hypertension, residing 
permanently in the metropolitan area of Lima, Peru (altitude <500 
m), were screened. Subjects were included if they fulfilled the fol-
lowing criteria: age between 18 and 65 years; permanent residence 
at low (<500 m) altitude; conventional systolic BP (SBP) between 
140 and 159 mm Hg or conventional diastolic BP (DBP) between 
90 and 99 mm Hg and mean daytime BP: 135≤SBP<150 mm Hg 
or 85≤DBP<95 mm Hg in the absence of antihypertensive treat-
ment (see below); written informed consent was obtained to par-
ticipate in the study. We excluded subjects who would likely have 
BP in moderate to severe range after washout, those with contra-
indications to either study drug, with history of serious mountain 
sickness, recently exposed to high altitude, with secondary hyper-
tension or other relevant diseases, severe obesity and pregnant 
women (detailed criteria are available in Box S1 in the online-only 
Data Supplement).
All subjects underwent a general health check before the expe-
dition. The protocol was approved by the Ethics Committees of 
participating institutions in Italy and Peru and by Peruvian Drug 
Agency. The study was conducted in agreement with Declaration 
of Helsinki principles.
Study Organization
Subjects’ eligibility criteria were assessed at the screening visit at sea 
level (visit 0). A baseline sea level visit (visit 1) was then performed 
(after 4 weeks washout in treated subjects), after which eligible 
subjects were randomized to placebo or active treatment group and 
remained on the assigned treatment until study end. Two sea level 
visits were then performed: visit 2 (safety visit, 2 weeks) and visit 
3 (6 weeks) when study assessments were repeated. Two to 10 days 
after visit 3, the participants were brought by car to high altitude 
(Huancayo, Peru, 3260 m) where they stayed for 3 days (2 nights) 
during which study assessments were repeated (visit 4). On the morn-
ing of the first or second day after the return to sea level, visit 5 took 
place during which conventional BP was measured and the ambula-
tory BP monitor was placed. The details on the design of the study are 
shown in Figure 1 and Figure S1 in the online-only Data Supplement.
Study Drugs
Commercially available tablets of nifedipine gastrointestinal thera-
peutic system 30 mg and telmisartan 80 mg were used in the active 
treatment arm, whereas sucrose was used as placebo. Active medica-
tions and placebo were placed in identical capsules to be taken in a 
single morning administration. Throughout the study, the use of other 
antihypertensive medication or of drugs aimed at preventing high-
altitude sickness was not allowed. In case of acute mountain sickness 
symptoms, an appropriate medical therapy was allowed.
Randomization and Blinding
A randomization list was generated before the study start. 
Randomization was performed within blocks including between 4 
and 8 participants, without stratification. At inclusion, each partici-
pant received consecutive identification code associated with one of 
the treatment groups. Throughout the study, all subjects and investi-
gators were blind to the treatment administered.
Measurements
Information collected during the study included clinical history, 
symptoms and adverse events, conventional BP and HR, 24-hour 
ambulatory BP and HR, respiratory rate, body height and weight, 
waist circumference, blood oxygen saturation (SpO2), Lake Louise 
Score of acute mountain sickness,18 and other variables, not discussed 
in this article.
Conventional BP and HR were obtained as the average of 2 seated 
measurements performed 1 to 2 minutes apart after at least 5 minutes 
of rest on the nondominant arm using a validated oscillometric device 
(UA-767 Plus; AND, Tokyo, Japan).19 Twenty-four–hour ambulatory 
BP monitoring was performed using validated oscillometric devices 
(TM-2430; AND, Tokya, Japan),20 applied to the nondominant arm 
in the morning and removed after 24 hours. At high altitude (visit 4), 
the device was always placed in the morning of the first day after the 
arrival, that is, after 13 to 17 hours of permanence (Figure S1). The 
subjects were instructed to attend at their usual activities during the 
monitoring period, while avoiding strenuous exercise. Measurements 
were programmed every 15 minutes during daytime (7–23 hours) and 
every 20 minutes at nighttime (23–7 hours). Mean values were com-
puted for SBP, DBP, and HR over 24 hours, daytime, and nighttime 
(defined based on subjects’ activity logbook). Nocturnal BP fall was 
calculated as percent reduction of mean BP at nighttime from the 
mean daytime value. Only recordings with at least 70% of expected 
Figure 1. Study design and visits. ABPM indicates ambulatory blood pressure monitoring.
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readings rated as valid were considered.21 Spot measurement of trans-
cutaneous blood oxygen saturation (SpO2) was performed during sea 
level visits and on day 1 (evening of the arrival day), day 2, and day 3 
(both in the morning) of high-altitude permanence with pulse oxim-
eter (RAD-5; Masimo Corp, Irvine, CA).
Study Variables
Twenty-four–hour ambulatory mean SBP at V4 was the primary effi-
cacy variable. Secondary efficacy variables included: 24-hour DBP, 
daytime, and nighttime mean SBP and DBP at high altitude (V4), 
24-hour, daytime, and nighttime mean SBP and DBP at sea level 
(V3); nocturnal fall of SBP and DBP at high altitude (V4) and at sea 
level (V3); conventional SBP and DBP at high altitude (V4) and at 
sea level (V3).
Safety variables included adverse events, vital signs, routine labo-
ratory blood tests performed during treatment and, at high altitude, 
additionally Lake Louise Score and SpO2.
Sample Size
On the basis of data from previous studies,8,17 we estimated that the 
primary efficacy variable (24-hour ambulatory SBP at high altitude) 
would have a SD of 12 mm Hg within each group. On the basis of 
this estimate, 84 patients (42 per each of the 2 treatment groups) were 
needed to identify an 8 mm Hg difference in the primary efficacy vari-
able between the study groups with a power of 80% and type I error 
rate of 0.05, assuming a 10% patient dropout. To account for a pos-
sible imprecision in the estimate of SD (based on studies in normo-
tensive subjects) and of dropout rate, we decided to recruit a total of 
50 subjects per group.
Statistical Analysis
The primary efficacy analysis was performed per protocol, ie, in 
subjects who had completed all study visits and showed no major 
protocol deviations. The safety analysis was performed in subjects in 
whom at least 1 dose of study medication was administered.
R software version 2.15.3 (R Foundation for Statistical Computing) 
was used. Continuous variables are reported as mean±SD or (in ad-
justed models) as least square mean±SE. Differences between groups 
at baseline were assessed for categorical variables with χ2 test and for 
continuous variables with unpaired 2-tailed Student t test.
To assess the combined effect of altitude level and treatment group, 
we used the linear mixed-effects models package (nlme, linear, and 
nonlinear mixed-effects models) accounting for repeated measure-
ments, with a compound symmetry covariance structure, fitting the 
models by maximizing the restricted log-likelihood. Visit 1 values 
were included as fixed effect in the linear mixed-effects models to 
reduce the error variance by accounting for individual differences in 
responses. For multiple post hoc comparisons, we used the Holm al-
gorithm.22 An α level of 0.05 was used for all hypothesis tests.
Results
Of 332 screened subjects, 100 fulfilled selection criteria and 
were randomized (age, 55.7±17.2 years; 59 men/41 women). 
Of those, 89 completed the study and were considered in the 
per-protocol analysis (Figure S2). There were no significant 
between-group differences at baseline except for a somewhat 
higher body weight (P=0.05) and body mass index (P=0.08) 
in the placebo group (Table 1).
Effects of High-Altitude in Untreated Subjects
Compared with prealtitude (visit 3) values, conventional and 
24-hour SBP and DBP were significantly higher at high alti-
tude (Figure 2). This increase tended to be more pronounced 
for ambulatory than for conventional BP (P for difference 
>0.10). The increase was greater during the night than during 
the daytime (SBP, 9.3 versus 14.0 mm Hg; P<0.02 and DBP, 
4.4 versus 7.5 mm Hg; P<0.01), with a marked reduction in 
the size of the nocturnal BP fall (for SBP from 15.5±7.4% to 
11.5±8%; P<0.05; Figure S3). The BP changes were accom-
panied by a significant increase in 24-hour, daytime, and 
nighttime mean HR, with an attenuation of the nocturnal bra-
dycardia. Increase in BP and HR occurring at altitude largely 
disappeared on return to sea level (visit 5) although 24-hour, 
daytime, and nighttime SBP values remained higher after than 
before altitude exposure (visit 3). Detailed information on BP 
and HR behavior is shown in Table 2 and Table S1.
Effects of Treatment
After 6 weeks of treatment at sea level, office and ambulatory 
BP showed, respectively, a small reduction and no reduction 
at all in the placebo group, whereas in the active treatment 
group, all BP values were significantly reduced. The 24-hour 
mean SBP value (primary efficacy variable) was thus lower 
with active treatment than with placebo at sea level (visit 
3) and remained significantly lower at high altitude (visit 4; 
147.9±11.1 mm Hg for placebo; 132.6±12.4 mm Hg for active 
treatment; P<0.001; 95% confidence interval of the differ-
ence: 10.9–19.9 mm Hg). Similar results were obtained for 
conventional SBP and DBP, for 24-hour DBP, and for daytime 
and night-time BP taken separately (Table 2; Figure 2; Table 
S1). The increase in conventional and 24-hour SBP at high 
altitude tended to be smaller in the active treatment group, 
but the difference was not significant (conventional, 2.5±15.0 
versus 7.8±15.2 mm Hg; P=0.10; 24-hour, 8.1±10.4 versus 
11.0±9.0 mm Hg; P=0.17 for active treatment and placebo, 
respectively). No differences in HR were observed between 
study groups. No sex-related differences were observed in the 
outcomes.
Safety Results
At sea level, adverse events occurred in 27 subjects: 18 in 
the active treatment and 9 in the placebo group. None of the 
adverse events were classified as serious except transient neu-
rological symptoms, which developed in 1 subject in placebo 
Table 1. Baseline Characteristics of Subjects Included in  
Per-Protocol Analysis
Variable All (n=89) T/N (n=47) PL (n=42)
P Value  
(T/N vs PL)
Age, y 51.7±8.9 51.5±8.4 52.1±9.5 > 0.20
Sex (M/F) 50/39 27/20 23/19 > 0.20
Height, cm 163.5±8.4 162.4±8.8 164.8±8.0 0.19
Weight, kg 76.1±13.7 73.5±13.9 79.1±13.0 0.05
BMI, kg/m2 28.3±3.6 27.7±3.5 29.0±3.5 0.08
Current smokers,  
n (%)
20 (22) 10 (21) 9 (21) > 0.20
History of  
dyslipidemia, n (%)
41 (46) 21 (45) 20 (48) > 0.20
Previous 
antihypertensive 
treatment, n (%)
25 (28) 14 (30) 11 (26) > 0.20
BMI indicates body mass index; F, female; M, male; PL, placebo; and T/N, 
telmisartan/nifedipine gastrointestinal therapeutic system.
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group, subsequently withdrawn from the study. The details on 
adverse events are shown in Table S2.
At high-altitude, there were no differences between groups 
in Lake Louise Score (median for both groups: first day: 1; 
second day: 2; and third day: 1), while SpO2 was higher in the 
active treatment than in placebo group (Figure 3).
Discussion
Our study shows for the first time that in hypertensive patients 
living at sea level under acute exposure to high altitude (1) 
a marked increase occurs in conventional and ambulatory 
BP, accompanied by a reduction in nocturnal BP fall; (2) the 
combination of 2 antihypertensive drugs (a blocker of the 
renin–angiotensin system and a long-acting calcium antago-
nist) although not able to abolish the pressor response to high-
altitude exposure, continues to exert a BP-lowering effect as it 
does at the sea level, with no tolerability and safety problems.
Except for very short exposures to hypoxia (where hypoxia-
dependent vasodilation may prevail), studies in animals and 
healthy normotensive individuals have repeatedly documented 
that conventional BP undergoes a marked increase during acute 
exposures to altitudes of ≥3000 m.23–27 In healthy normotensive 
subjects, an increase in ambulatory BP was also shown,17,28,29 
which becomes progressively more marked as the altitude 
increases, with a concomitant reduction, at high altitudes, of the 
nocturnal BP dipping.17 The present study shows that similar 
changes occur in hypertensive subjects, regardless of the pres-
ence of antihypertensive treatment. In several subjects in our 
study, 24-hour SBP increased at high altitude by >25 mm Hg 
with average daytime values exceeding 160 mm Hg. Although 
in our subjects with low risk at baseline, this was not associ-
ated with immediate safety issues, in individuals at higher car-
diovascular risk, the resulting marked increase in left ventricle 
afterload might be clinically relevant and could contribute to 
the increased risk of sudden death reported in skiers with pre-
existing hypertension acutely exposed to high altitude.30
In the present study (in line with what observed in normo-
tensive subjects17) under acute exposure to high altitude: (1) 
ambulatory BP increased more than conventional BP; this 
implies that studies relying on the traditional BP measurement 
method may underestimate the pressor effects of high altitude; 
(2) the BP increase was particularly marked during the night, 
presumably because at high altitude there is a further critical 
reduction in SpO2 during sleep,31 leading to further sympa-
thetic activation that opposes the sleep-induced hypotension.
Our study was not designed to investigate the mechanisms of 
BP increase at high altitude in hypertensive subjects. However, 
we think that it is reasonable to extrapolate the information 
obtained in normotensive subjects and showing that (1) vasocon-
striction causes by chemoreflex-mediated sympathetic activation 
seems the single most important mechanism involved; (2) other 
pressor mechanisms, which may play a role, include increased 
arterial stiffness, endothelin secretion, and blood viscosity; (3) 
renin–angiotensin–aldosterone system is not likely to be acti-
vated.4,17 Apart from hypoxia, other factors associated with high-
altitude environment may have contributed to the observed BP 
changes. Daytime ambient temperature was lower by about 6°C 
at high altitude than at sea level; however, based on the results of 
previous studies,32,33 its contribution to BP increase in our study 
probably did not exceed 2 mm Hg. Psychological stress related 
to change of environment could have some relevance, too. Sleep 
quality and duration might affect nighttime BP but we observed 
no such relationship. Other potentially relevant factors could 
include the occurrence of sleep apneas, degree of physical activ-
ity, and previous exposures to high altitude.
Interestingly, we observed a marked reduction of noctur-
nal BP dipping at about 3300 m in hypertensive subjects, 
whereas in the normotensive participants of the HIGHCARE-
HIMALAYA study, a clear-cut blunting of the nighttime BP 
fall was only observed at a higher altitude of 5400 m.17 Such 
a discrepant behavior may have 2 possible explanations: (1) 
SpO2 decrease at night is larger in hypertensive than in nor-
motensive subjects or (2) hypertensive subjects have greater 
chemoreflex sensitivity.34
Another novel and clinically relevant contribution of our 
study is the information on the BP effects at high altitude 
Figure 2. Mean 24-hour systolic blood pressure (SBP; primary outcome) and diastolic blood pressure (DBP) at 4 study visits in 
participants receiving active treatment (black circles) or placebo (open squares). Comparisons vs visit 3 (sea level, on treatment): 
§§P<0.001, §P<0.01. Comparisons active vs placebo: #P<0.001.
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Table 2. BP and HR Variables Derived From Conventional Measurements and From 
24-Hour Ambulatory BP Monitoring in Telmisartan/Nifedipine GITS (n=47) and Placebo 
Group (n=42)
Variable Group Baseline (V1)
Sea Level on 
Treatment (V3)
High Altitude  
(V4)
Return to Sea 
Level (V5)
SBP
 Conv., mm Hg Placebo 141.4±12.1 137.9±14.5 145.8±13.7* 137.7±12.8
Active 141.0±12.7† 123.3±14.1 125.8±11.8 123.6±15.5
P value >0.20 <0.001 <0.001 <0.001
 24 h, mm Hg Placebo 137.6±8.6 137.0±10.0 147.9±11.1† 141.9±11.6*
Active 137.6±7.8† 125.1±10.1 132.6±12.4† 126.7±13.1
P value >0.20 <0.001 <0.001 <0.001
 Day, mm Hg Placebo 144.1±7.8 143.9±8.6 153.3±10.3† 148.2±10.9‡
Active 143.6±7.5† 132.0±10.0 138.0±11.1† 133.3±13.6
P value >0.20 <0.001 <0.001 <0.001
 Night, mm Hg Placebo 122.7±13.4 121.7±14.5 135.7±15.9† 128.4±16.6*
Active 123.5±11.4† 110.4±11.9 119.8±18.1† 111.3±14.6
P value >0.20 <0.001 <0.001 <0.001
 Dip, % Placebo 14.9±6.6 15.5±7.4 11.5±8.0‡ 13.4±8.5
Active 14.1±6.0 16.3±6.4 13.3±8.8.0 16.6±7.6
P value >0.20 >0.20 >0.20 >0.20
DBP
 Conv., mm Hg Placebo 90.9±8.1 88.9±10.7 92.2±10.5 87.9±11.2
Active 91.0±8.2† 80.6±10.4 83.5±9.2 79.1±9.7
P value >0.20 <0.001 <0.001 <0.001
 24 h, mm Hg Placebo 83.4±6.8 82.4±7.4 88.0±6.8† 84.6±8.4
Active 83.9±7.1† 76.3±6.4 80.7±8.2† 77.2±7.9
P value >0.20 <0.001 <0.001 <0.001
 Day, mm Hg Placebo 87.6±6.8 86.9±7.0 91.3±6.9† 88.8±8.3
Active 87.8±7.4† 80.4±6.5 83.7±7.9* 81.4±8.4
P value >0.20 <0.001 <0.001 <0.001
 Night, mm Hg Placebo 73.7±9.1 72.7±9.9 80.2±9.4† 75.2±10.3
Active 74.6±8.6† 67.3±7.7 73.5±10.6† 67.5±8.3
P value >0.20 0.023 0.004 <0.001
 Dip, % Placebo 15.7±8.7 16.4±8.9 12.1±8.5‡ 15.4±8.5
Active 15.0±7.0 16.2±7.5 12.1±8.2‡ 17.0±7.5
P value >0.20 >0.20 >0.20 >0.20
HR
 24 h, bpm Placebo 75.6±8.6 78.1±7.8 86.5±8.5† 75.0±8.2‡
Active 74.1±7.6 77.0±7.3 85.3±9.2† 76.8±8.2
P value >0.20 >0.20 >0.20 >0.20
 Day, bpm Placebo 80.0±8.8 82.8±7.7 89.9±8.4† 78.6±8.1*
Active 78.2±7.9‡ 81.7±7.5 88.8±9.2† 81.0±8.6
P value >0.20 >0.20 >0.20 >0.20
 Night, bpm Placebo 66.1±9.6 67.8±9.4 79.2±10.5† 66.9±9.5
Active 64.3±8.1 67.1±8.2 76.9±10.3† 66.7±8.1
P value >0.20 >0.20 >0.20 >0.20
 Dip, % Placebo 17.4±7.4 18.2±7.7 12.0±7.4† 15.1±6.9
Active 17.7±7.0 17.8±7.2 13.2±6.9* 17.2±7.2
P value >0.20 >0.20 >0.20 >0.20
Ambulatory BP data are separately shown for 24 hours, daytime, nighttime, as well as for nocturnal fall 
(dip, shown as percentage of daytime mean level). Data are shown as mean±SD. P values in the table refer 
to contrasts between groups for each condition. DBP indicates diastolic blood pressure; GITS, gastrointestinal 
therapeutic system; HR, heart rate; and SBP, systolic blood pressure.
Symbols of statistical significance refer to contrasts between visit 3 versus remaining study conditions: 
*P<0.01, †P<0.001, ‡P<0.05. 
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of a commonly used and guideline-supported combina-
tion treatment between an ARB and a slow release calcium 
antagonist.16,17 Two previous studies reported that β-blockers 
have a limited effect in preventing the 24-hour BP increase 
that occurs at high altitude,8,28 and their use (particularly of 
carvedilol) is associated with lower SpO2, worse tolerabil-
ity, and exercise capacity.8,35 In the healthy participants of 
HIGHCARE-HIMALAYA, we observed that BP-lowering 
effect of telmisartan monotherapy was maintained ≤3400 
m but not at higher altitudes (5400 m), with no tolerability 
issues.17 In the hypertensive participants of the present study, 
the combined treatment with telmisartan and nifedipine was 
effective and safe at an altitude (3260 m) similar to the lower 
altitude reached in HIGHCARE-HIMALAYA, with BP val-
ues that remained lower than in placebo-treated subjects, as 
it occurred at sea level. Moreover, the active treatment group 
had higher SpO2 at high altitude (possibly because of the dila-
tory effect of nifedipine on pulmonary vasculature leading to 
improved ventilation:perfusion ratio), even if no differences 
in acute mountain sickness were found between treatment 
groups.
Our study has several elements of strengths including: (1) 
adequate sample size, (2) controlled double-blind design, and 
(3) assessment of the BP effect of high altitude and treatment 
by ambulatory BP monitoring, an approach that is prognos-
tically superior to conventional BP measurements16 and that 
better reflects the high altitude–related BP alterations.17 The 
study also has some inevitable limitations. First, for practi-
cal reasons, we could not assess whether the pressor effect of 
high altitude and the efficacy of antihypertensive treatment in 
this setting are maintained over longer time periods. Second, 
because of safety concerns, we could not verify the possibility 
of a loss or decrease of treatment efficacy at higher altitudes, 
an observation we previously made in normotensive patients 
under ARB administration.17 However, our study reflects a 
common real-life situation (skiing, hiking, work-, or tourism-
related trips) in which patients with hypertension are exposed 
to altitudes of 2500 to 3500 m for up to a few days. Third, 
our subjects were sampled from the local population, which 
means that the results cannot be easily generalized to other 
populations, whose different genetic background might deter-
mine different responses to hypoxia and BP-lowering drugs. 
However, our patients were of mixed ethnic origin and they 
lived permanently at sea level, with thus no high-altitude 
adaptation. Furthermore, native Andean populations show a 
lower degree of genetic adaptation to high-altitude environ-
ment when compared, for example, with Tibetans, ie, ethnic 
groups characterized by a longer history of altitude expo-
sure.36 Therefore, we think that the genetic background of our 
population had no relevant impact on the results. Finally, the 
accuracy of oscillometric devices at high altitude is largely 
unknown although our yet unpublished data indicate that it is 
not meaningfully affected.
Perspectives
Our findings support the recommendation that hypertensive 
subjects with low baseline cardiovascular risk may be safely 
exposed to moderately high altitude for short periods of time 
if properly treated. Combination of a calcium antagonist and 
an ARB seems safe and effective in this setting.
Major knowledge gaps still remain in this area and further 
studies are needed (1) to assess the safety of high-altitude 
exposure in controlled hypertensive subjects in higher risk 
categories; (2) to assess safety and efficacy of other classes of 
cardiovascular drugs at high altitude, also considering differ-
ent altitudes and longer duration of exposure.
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What Is New?
•	The direct demonstration of changes in 24-hour blood pressure in 
hypertensive subjects exposed to high altitude. The demonstration of 
antihypertensive treatment efficacy in this setting.
What Is Relevant?
•	Demonstration that nifedipine gastrointestinal therapeutic system/
telmisartan combination is safe and maintains its BP-lowering effect in 
hypertensive subjects acutely exposed to high altitude, even if it does 
not prevent an increase in blood pressure.
Summary
Hypertensive patients who plan brief permanence at high altitude 
may expect blood pressure to increase. If they receive treatment 
with dihydropyridine calcium antagonist and angiotensin receptor 
blocker, its efficacy should be maintained.
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Box S1. Detailed exclusion criteria: 
 conventional SBP ≥150 mmHg and/or conventional  DBP ≥95 mmHg in treated subjects;  
 regular use of two or more antihypertensive drugs (with the exception of subjects on two 
antihypertensive drugs in low doses);  
 treated antihypertensive subjects in whom withdrawal of treatment was deemed unethical; 
 contraindications to ARBs or calcium antagonists;  
 history of serious mountain sickness;  
 continuous exposure for more than one week to altitudes above 2500 m during the 3 months 
preceding inclusion in the study;  
 cardiovascular diseases other than hypertension;  
 suspected or confirmed secondary hypertension;  
 diabetes mellitus;  
 serious respiratory disorders;  
 other conditions deemed relevant by the investigators;  
 body mass index  ≥35 kg/m2;  
 upper arm circumference >32 cm;  
 known severe obstructive sleep apnea;  
 pregnancy;  
 premenopausal women not using effective contraceptive methods;  
 elevated probability of noncompliance with the study procedures. 
 
 
  
Table S1. Blood pressure (BP) and heart rate (HR) variables derived from conventional measurements and from 24h ambulatory BP monitoring in 
telmisartan/nifedipine GITS (N=47) and placebo group (N=42). Ambulatory BP data are separately shown for 24 hours, daytime, night-time as well as for 
nocturnal fall (dip, shown as percentage of daytime mean level).  Data are shown as mean ± SD. P values in the table refer to contrasts between groups for each 
condition. Overall effects of visit, treatment and their interaction are shown in the last three columns. Symbols of statistical significance refer to contrasts 
between Visit 3 vs. remaining study conditions:  *** p<0.001, ** p<0.01, * p<0.05; bpm - beats per minute 
 
Variable Group Baseline (V1) Sea-level on 
treatment (V3) 
High altitude (V4) Return to sea level 
(V5) 
Effect p value  
   
Visit Treatment Visit x 
treatment 
SBP Conv. Placebo  141.4±12.1 137.9±14.5 145.8±13.7 ** 137.7±12.8    
 
(mmHg) Active  141±12.7 *** 123.3±14.1 125.8±11.8 123.6±15.5    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
24h Placebo  137.6±8.6 137±10 147.9±11.1 *** 141.9±11.6 **    
 
(mmHg) Active 137.6±7.8 *** 125.1±10.1 132.6±12.4 *** 126.7±13.1    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Day Placebo  144.1±7.8 143.9±8.6 153.3±10.3 *** 148.2±10.9 *    
 
(mmHg) Active 143.6±7.5 *** 132±10 138±11.1 *** 133.3±13.6    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Night Placebo  122.7±13.4 121.7±14.5 135.7±15.9 *** 128.4±16.6 **    
 
(mmHg) Active 123.5±11.4 *** 110.4±11.9 119.8±18.1 *** 111.3±14.6    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Dip Placebo  14.9±6.6 15.5±7.4 11.5±8 * 13.4±8.5    
 (%) Active 14.1±6 16.3±6.4 13.3±8.8 16.6±7.6    
  P value >0.20 >0.20 >0.20 >0.20 0.001 0.30 0.14 
DBP Conv. Placebo  90.9±8.1 88.9±10.7 92.2±10.5 87.9±11.2    
 
(mmHg) Active 91±8.2 *** 80.6±10.4 83.5±9.2 79.1±9.7    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
24h Placebo  83.4±6.8 82.4±7.4 88±6.8 *** 84.6±8.4    
 
(mmHg) Active 83.9±7.1 *** 76.3±6.4 80.7±8.2 *** 77.2±7.9    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Day Placebo  87.6±6.8 86.9±7 91.3±6.9 *** 88.8±8.3    
 
(mmHg) Active 87.8±7.4 *** 80.4±6.5 83.7±7.9 ** 81.4±8.4    
  P value >0.20 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Night Placebo  73.7±9.1 72.7±9.9 80.2±9.4 *** 75.2±10.3    
 
(mmHg) Active 74.6±8.6 *** 67.3±7.7 73.5±10.6 *** 67.5±8.3    
  P value >0.20 0.023 0.004 <0.001 <0.001 0.006 <0.001 
 
Dip Placebo  15.7±8.7 16.4±8.9 12.1±8.5 * 15.4±8.5    
 
(%) Active 15±7 16.2±7.5 12.1±8.2 * 17±7.5    
  P value >0.20 >0.20 >0.20 >0.20 <0.001 0.89 0.61 
HR 24h Placebo  75.6±8.6 78.1±7.8 86.5±8.5 *** 75±8.2 *    
 
(bpm) Active 74.1±7.6 77±7.3 85.3±9.2 *** 76.8±8.2    
  P value >0.20 >0.20 >0.20 >0.20 <0.001 0.73 0.09 
 Day Placebo  80±8.8 82.8±7.7 89.9±8.4 *** 78.6±8.1 **    
 
(bpm) Active 78.2±7.9 * 81.7±7.5 88.8±9.2 *** 81±8.6    
  P value >0.20 >0.20 >0.20 >0.20 <0.001 0.77 0.04 
 
Night Placebo  66.1±9.6 67.8±9.4 79.2±10.5 *** 66.9±9.5    
 
(bpm) Active 64.3±8.1 67.1±8.2 76.9±10.3 *** 66.7±8.1    
  P value >0.20 >0.20 >0.20 >0.20 <0.001 0.47 0.51 
 
Dip Placebo  17.4±7.4 18.2±7.7 12±7.4 *** 15.1±6.9    
 
(%) Active 17.7±7 17.8±7.2 13.2±6.9 ** 17.2±7.2    
  P value >0.20 >0.20 >0.20 >0.20 <0.001 0.49 0.58 
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Table S2. Summary of adverse events (T/N – telmisartan+nifedipine; PL – placebo) 
Adverse event T/N PL All 
Headache 10 7 17 
Constipation 5 2 7 
Dizziness 3 0 3 
Feeling of warmth 3 0 3 
Musculoskeletal symptoms (pain, weakness) 3 3 6 
Neurological symptoms 0 1 0 
Leg edema 1 0 1 
GI symptoms 1 0 1 
Anxiety 0 1 1 
Cough 1 0 1 
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Figure S1. Detailed timing of high altitude exposure (Visit 4) and of study assessments during this visit. 
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Figure S2. Flow of subjects in the study. 
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Not eligible 
(n=232) 
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(n=100) 
50 assigned to telmisartan 80 
mg/nifedipine GITS 30 mg 
50 assigned to placebo 
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2 consent withdrawal 
1 noncompliance 
42 completed 47 completed  
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3 consent withdrawal 
2 noncompliance 
1 loss to follow-up 
1 adverse event 
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Figure S3. Averaged hourly systolic blood pressure (SBP) profiles at sea level without treatment (dotted  
line), at sea level on-treatment (dashed line) and at high altitude on treatment (solid line) in subjects on 
active treatment (upper panel) or placebo (lower panel).  Data are shown as unweighted averages with 
surrounding areas representing standard errors. Horizontal lines represent the accepted values for defining 
hypertension in relation to daytime (135 mmHg) and night-time SBP (120 mmHg). 
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